Following the integration of immunotherapy into the treatment paradigm of triple-negative breast cancer, a multidisciplinary panel of experts, brought together by the Society for Immunotherapy of Cancer, published the first clinical practice guidelines focused on navigating clinical decisions with immunotherapy in breast cancer.
The combination of cabozantinib and nivolumab as a neoadjuvant regimen led to encouraging margin-negative resection and major pathological response rates in patients with hepatocellular carcinoma, according to results of a single-arm, phase 1b study that were published in Nature Cancer.
The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.
The FDA has granted an orphan drug designation to gavocabtagene autoleucel as a potential treatment for patients with cholangiocarcinoma.
It is difficult to overstate the confusion associated with our nation’s messaging regarding a well-considered, rational, and scientifically based public health–focused approach to the current and future ramifications of the COVID-19 pandemic.
The combination of pevonedistat plus azacitidine as a frontline treatment for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low-blast acute myeloid leukemia did not achieve predefined statistical significance for the primary end point of event-free survival in the phase 3 PANTHER trial.
Valentina Baez Sosa, MD, shares how her early life experiences in gymnastics and coaching have helped her become a better hematology/oncology physician.
An increase in the use of concurrent chemoradiation followed by durvalumab was found in patients with stage III non–small cell lung cancer who were treated at 3 Dutch centers in The Netherlands between 2015 and 2019.
The FDA has approved zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.
The rolling submission of a biologics license application to support the approval of both toripalimab plus gemcitabine- and cisplatin-based chemotherapy as a first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, as well as toripalimab monotherapy for the second-line or beyond treatment of patients with recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemotherapy has been completed.
More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.
The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.
Jay M. Lee, MD, discusses the implications of the ADAURA trial in early-stage resectable NSCLC, the importance of molecular testing, and the need for a multidisciplinary approach in this population.
Zanidatamab is being combined with tucatinib and capecitabine in a new cohort of a phase 1 trial of patients with locally advanced and/or metastatic HER2-positive breast cancer.
When George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.
The neo–epitope-based vaccine Tedopi is under investigation either alone or in combination with pembrolizumab as maintenance treatment vs best supportive care in patients with recurrent ovarian cancer following platinum-based chemotherapy as part of the phase 2 TEDOVA trial.
The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.
The FDA has granted a full approval to pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.
Despite an outsized reputation fueled by late-night commercials from personal injury lawyers, mesothelioma is a rare disease with approximately 3000 new diagnoses every year in the United States.
During the height of the COVID-19 pandemic, Black patients were significantly less likely to undergo prostate cancer surgery compared with White patients, highlighting potential systemic inequities in care across medical specialties, and providing further rationale to recognize and the unintended diversion in cancer care due to the pandemic.
The addition of veliparib to platinum-based chemotherapy in the frontline treatment of current smokers with advanced squamous non–small cell lung cancer did not significantly improve overall survival, but the LP52 signature may identify a subset of patients who will derive benefit from the combination.
Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents
The addition of berzosertib to standard cisplatin/gemcitabine did not improve progression-free survival compared with chemotherapy alone in patients with metastatic urothelial cancer.
Bharat Sanders sheds light on how patient-centered medical education put him behind the eyes of the patient and fundamentally changed the way he practices medicine.
The addition of venetoclax to daratumumab, bortezomib, and dexamethasone or daratumumab and dexamethasone alone led to a response rate of more than 90% in patients with relapsed/refractory multiple myeloma, which proved durable in the majority of patients, particularly those with t(11;14) translocation.
Co-occurring focal 22q11.22 deletions and IKZF1 alterations were associated with inferior outcomes vs IKZF1 alterations alone in pediatric patients with B-cell acute lymphoblastic leukemia.
The FDA has granted an orphan drug designation to LP-184 as a potential therapeutic option for patients with glioblastoma multiforme and other malignant gliomas.
Jennifer K. Litton, MD, discusses the rationale for examining neoadjuvant talazoparib in patients with BRCA1/2-positive, early HER2-negative breast cancer, safety and efficacy results from NEOTALA, and next steps for research.
Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, was recently awarded a Specialized Program of Research Excellence grant of $50,000 for a pilot project examining differences in risk and disease course for Black versus white head and neck cancer patients.
The United Kingdom’s National Institute for Health and Care Excellence will not recommend daratumumab plus bortezomib, thalidomide, and dexamethasone for use as induction and consolidation treatment in adult patients with untreated multiple myeloma, when an autologous stem cell transplant is suitable.
